Unavailable · 30.10.2026
Supply shortage Belgium: Lenzetto 1.53 mg/dose transderm. spray sol. met. pump 6.5 ml (56 doses) – Unavailable, 30.10.2026 · ENR FAMHP-ID 6ac742bfd9584e6836660f60; BE478426
Affected country: Belgium · Reported period: 07.10.2026 – 06.11.2026 · Active ingredient: Estradiol
Active ingredients
Notice context
A supply shortage has been recorded for Lenzetto 1.53 mg/dose transderm. spray sol. met. pump 6.5 ml (56 doses) in Belgium. The stated reason is “Logistikprobleme (Transport, Zoll usw.)”. The notice concerns the active ingredient Estradiol and is not identified as hospital-relevant.
This information describes the reported supply status and is not medical or pharmaceutical treatment advice. Availability, alternatives and further measures must be assessed for each individual case by the responsible pharmaceutical market participants.
Official shortage notice for Belgium. Responsibility and update procedures follow the information supplied by the relevant authority.
Check the official notice list →Implications for procurement and the supply chain
The notice for Lenzetto 1.53 mg/dose transderm. spray sol. met. pump 6.5 ml (56 doses) is a supply signal concerning Estradiol in Belgium. The published reason “Logistikprobleme (Transport, Zoll usw.)” determines which data should be verified first.
For delivery or distribution issues, handover points, transport routes, temperature control, customs status, recipient authorisation and confirmed lead times should be checked.
Once a lawful sourcing route is confirmed and buffer stock is required, our pharma warehouse in Cheb page explains receipt, stock control and picking. For delivery or distribution issues, the temperature-controlled pharmaceutical transport workflow sets out the route, handovers and evidence to agree in advance.
Decision route for this supply case
- Confirm the notice, product identity, period and actual demand with the primary source and accountable market participants.
- Assess handover points, alternative routes, temperature, customs and recipient status, and confirmed lead times.
- Document release, stock status, GDP evidence, warehousing and transport process, and escalation responsibility.
Inter-Pharma can structure the B2B case, potential sourcing and warehousing routes, and operational implementation. Clinical decisions, regulatory permissibility, product release and actual availability remain with the accountable parties.
Request a structured supply review →Operational shortage resilience: GDP warehousing and pharmaceutical storage
For distribution disruption, defined stock for Lenzetto 1.53 mg/dose transderm. spray sol. met. pump 6.5 ml (56 doses) in Cheb can support confirmed alternative routes to Belgium.
Inter-Pharma combines GDP-oriented pharmaceutical storage in Czechia with batch and expiry control, FEFO, stock status, picking and dispatch preparation in its own Cheb operation.
Storage at 15–25 °C or any 2–8 °C requirement is derived solely from the product specification and confirmed for the project.
Operational checks for this notice
- Match product identity using CNK 3466489, active ingredient, strength, dosage form and pack.
- Confirm the reported status and the period 07.10.2026 to 06.11.2026 with the primary source and potential suppliers.
- Document demand, stock coverage, open orders and lawful alternative or sourcing routes for the specific case.
- Clarify temperature, batch, expiry, stock status, recipient authorisation and GDP evidence before cross-border supply.
Relevant services and specialist pages
The following B2B topics are particularly relevant when handling a shortage involving Lenzetto 1.53 mg/dose transderm. spray sol. met. pump 6.5 ml (56 doses):